Entera Bio Ltd. (ENTX) SEC Filings

Entera Bio Ltd. (ENTX) is registering for resale, under a Form S-3 shelf, up to 134,803,910 ordinary shares offered by existing selling shareholders. This total consists of 122,961,215 ordinary shares already issued and up to 11,842,695 ordinary shares issuable upon exercise of Pre-Funded Warrants issued in a July 28, 2026 private placement.

The selling shareholders may sell shares from time to time using various methods, and Entera will not receive any proceeds from these resales, though it will cover registration expenses. Entera’s ordinary shares trade on Nasdaq under the symbol “ENTX”; the closing price was $3.08 on August 27, 2026.

The company highlights significant political, security and economic risks in the Middle East, as its principal research facilities and many key personnel are in Israel. Its auditors have included an explanatory paragraph regarding Entera’s ability to continue as a going concern in the 2025 financial statements, and investors are directed to detailed risk factors incorporated by reference.

Entera Bio Ltd. (ENTX) has filed a shelf resale registration covering up to 134,803,910 ordinary shares that may be offered from time to time by existing holders from a July 28, 2026 private placement. The registered shares consist of 122,961,215 ordinary shares and up to 11,842,695 ordinary shares issuable upon exercise of Pre-Funded Warrants. Entera states it will not receive any proceeds from sales of these shares by the selling shareholders, though it will bear the registration fees and related offering expenses.

The ordinary shares trade on Nasdaq under the symbol ENTX, and the closing price on August 20, 2026 was $3.22 per share. As context, Entera reports 173,834,271 ordinary shares outstanding as of August 17, 2026 and authorized capital of 350,000,000 ordinary shares. The filing emphasizes significant risk factors, including extensive recent and ongoing security, political and economic instability in the Middle East that could adversely affect its Israel-based operations. The company’s independent auditor’s report for the year ended December 31, 2025 includes an explanatory paragraph regarding Entera’s ability to continue as a going concern.

Entera Bio Ltd. (ENTX) reported an initial statement of beneficial ownership for Riccardo Paolo Camisasca, who serves as Chief Medical Officer. The Form 3 lists him as an officer but does not report any equity transactions, holdings tables, or derivative positions at this time.

Entera Bio Ltd. appointed Riccardo Paolo Camisasca, M.D. as Chief Medical Officer effective August 18, 2026. He brings more than 30 years of experience in clinical development, medical affairs, regulatory strategy and R&D leadership, including serving as Global Head of R&D at Sumitomo Pharma Switzerland and prior senior roles at Bial, Syneos Health, Takeda and Novartis.

The appointment is positioned to support late-stage development of Entera’s lead oral peptide candidate EB613, an oral PTH(1-34) tablet for osteoporosis. A 6‑month, 161‑patient, placebo-controlled Phase 2 study of EB613 met primary biomarker and secondary BMD endpoints without significant safety concerns, and the company is planning Phase 3 initiation.

Entera Bio Ltd., an Israel-incorporated biotechnology company, reported a completed exempt securities offering under Regulation D Rule 506(b). The company sold $274,999,976 of securities, consisting of an aggregate of 122,961,215 Ordinary Shares and 11,842,695 pre-funded warrants, with no remaining amount to be sold. The first sale occurred on July 28, 2026. The offering involved equity, options/warrants, and the underlying ordinary shares, with multiple investment banks identified for sales compensation and no finders’ fees reported.

Entera Bio Ltd. reported that director Steven D. Rubin received equity compensation consisting of 19,117 ordinary shares granted in lieu of cash director fees for the first two quarters of 2026 and two stock option awards for 33,368 and 43,405 shares at an exercise price of 1.37 per share. The options, expiring on May 7, 2036, were approved after shareholder authorization and a Form S-8 registration and vest over one- and three-year schedules beginning February 1, 2026, with full acceleration upon a Change in Control. Following the share grant, Rubin directly owns 34,117 ordinary shares.

Malca Yonatan reported acquisition or exercise transactions in this Form 4 filing.

Entera Bio Ltd. reported that director Yonatan Malca received a grant of 22,815 Ordinary Shares on August 7, 2026. The award, priced at $0.0000 per share, was issued in lieu of cash fees for serving as director for the first and second quarters of 2026. Following this grant, Malca directly holds 100,231 Ordinary Shares. The Board approved the grant on August 5, 2026, subject to effectiveness of a Registration Statement on Form S-8, which occurred on August 7, 2026.

Taitel Haya reported acquisition or exercise transactions in this Form 4 filing.

Entera Bio Ltd. reported that director Haya Taitel received a board-approved grant of 20,790 ordinary shares on August 7, 2026. The shares were awarded in lieu of cash director fees for the first and second quarters of 2026, after the company filed a Form S-8 registering them. Following this compensation grant, Taitel directly holds 119,269 ordinary shares; the grant carried a reported price of $0.00 per share.

Entera Bio Ltd. director Sean Ellis reported equity compensation awards. He received 20,034 ordinary shares in lieu of cash board fees for the first and second quarters of 2026, after Board approval and a Form S-8 filed on August 7, 2026. He was also granted fully vested options for 40,000 ordinary shares at an exercise price of $1.37 per share, approved earlier in 2026 subject to shareholder approval and the same Form S-8. After these grants, he directly owns 208,132 ordinary shares and holds options for 40,000 shares.